Biotech · Private company
Acorda Therapeutics
Track this companyFree. Adds Acorda Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials90 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- CVT-301Phase 3 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CVT-301 High DosePhase 3 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CVT-301 Low DosePhase 3 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- dalfampridine-ER 10 mgPhase 3 · Post-ischemic StrokeClinicalTrials.gov · fetched Nov 12, 2026
- dalfampridine-ER 7.5 mgPhase 3 · Post-ischemic StrokeClinicalTrials.gov · fetched Nov 12, 2026
- Fampridine-SRPhase 3 · Spinal Cord InjuryClinicalTrials.gov · fetched Nov 12, 2026
- Observational cohortPhase 3 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- MoxifloxacinPhase 2 · SpasticityClinicalTrials.gov · fetched Nov 12, 2026
- TizanidinePhase 2 · SpasticityClinicalTrials.gov · fetched Nov 12, 2026
- CVT-301Phase 1 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SinemetPhase 1 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)PHASE1 · COMPLETED · started Mar 5, 2019ClinicalTrials.gov NCT03887884 · fetched Nov 12, 2026
- Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.PHASE3 · TERMINATED · started Apr 10, 2017ClinicalTrials.gov NCT03051607 · fetched Nov 12, 2026
- Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.PHASE3 · TERMINATED · started Apr 1, 2015ClinicalTrials.gov NCT02422940 · fetched Nov 12, 2026
- Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesPHASE3 · COMPLETED · started Mar 1, 2015ClinicalTrials.gov NCT02242487 · fetched Nov 12, 2026
- Randomized Safety Study of CVT-301 Compared to an Observational Control GroupPHASE3 · COMPLETED · started Mar 1, 2015ClinicalTrials.gov NCT02352363 · fetched Nov 12, 2026
- SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)PHASE2 · COMPLETED · started Dec 22, 2014ClinicalTrials.gov NCT02258152 · fetched Nov 12, 2026
- Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesPHASE3 · COMPLETED · started Nov 1, 2014ClinicalTrials.gov NCT02240030 · fetched Nov 12, 2026
- A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG TrialPHASE2 · COMPLETED · started Apr 1, 2013ClinicalTrials.gov NCT01839279 · fetched Nov 12, 2026
- Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord InjuryPHASE3 · COMPLETED · started Jul 1, 2002ClinicalTrials.gov NCT00041717 · fetched Nov 12, 2026